Umbilical cord blood (CB) is a useful stem cell source for patients without matched family donors. CB banking is expensive, however, because only a small percentage of the cord units stored are used for transplantation. In this study, we determined whether maternal factors, such as race, age, and smoking status have an effect on laboratory parameters of hematopoietic potential, such as viability, cell counts, CD34
teer donors in the NMDP, there is an average of 3000 patients searching at any given time and only 1300 unrelated bone marrow transplants each year. Thus, less than 50% of patients are able to find an unrelated bone marrow donor and proceed to transplant in a timely fashion. 6 Placental cord blood has been shown to contain sufficient progenitor cells to provide durable engraftment. 7 The first related cord blood transplant was performed in 1988. 8 The largest single institution experience is at Duke University. 9 Rubinstein et al 10 have recently reported on the results of 562 cord blood transplants facilitated by the New York Blood Center. In this study, engraftment was dependent upon the nucleated cell count of the cord blood unit. In the Eurocord study of 60 unrelated cord blood transplants, again the nucleated cell dose/kg infused correlated with engraftment. 11 As a response to the initial encouraging clinical results of cord blood transplants, several cord blood banks have been established worldwide. [12] [13] [14] [15] Programs have been funded by both private and public organizations, but the limited resources available force the cord blood banks to limit the number of cord blood units to process and freeze. In this study, we determined the optimal cord blood units based on maternal and neonatal factors. This information will allow cord blood banks to optimize cord blood unit selection and conserve resources.
Materials and methods

Umbilical cord blood collection
Umbilical cord blood was obtained from single birth, term, low risk deliveries at UMass Memorial Health Care, St Vincent's Hospital, and other affiliated hospitals of the American Red Cross Cord Blood Program. Every mother signed a Human Subjects Committee approved consent form prior to collection. Three thousand seven hundred and forty-five women enrolled in the American Red Cross Cord Blood Program between January 1997 and September 1998. Over half of the cord blood units were not frozen for transplantation because they did not meet the standards of the American Red Cross Cord Blood Program (eg volume less than 40 cc cord blood, positive bacterial culture, positive infectious disease marker). Complete maternal and neonatal data were available for 1269 of the 1310 processed cord blood units. Extensive medical and family history was obtained from the mother prior to collection, and labor and delivery data were obtained as well. Specifically, women were asked to self-report the use of cigarette smoking during pregnancy, the number of prior pregnancies and live births, their age and their race, in addition to detailed information of their family and genetic history, and the standard information (drug, travel, sexual, exposure history etc) asked of any blood donor. After delivery, a nurse reported to the program the weight and gestational age of the baby.
Infants were delivered according to normal obstetrical practices, and the cord blood was collected with the placenta in utero. For cesarian deliveries, the cord blood was collected from the surgical field after the delivery of the placenta. The cord was cleaned for 10 s each with alcohol and Betadine. A 16-gauge needle from a standard blood donor set containing 35 ml of citrate phosphate dextrose (CPD) anticoagulant (Baxter Health Care, Deerfield, IL, USA) was inserted into the umbilical vein; blood was allowed to flow by gravity, and the needle was removed when the blood flow ceased.
Laboratory processing
Blood from the mother and from the cord blood collection was reserved for HLA typing. After removal of aliquots for routine testing, including cell counts, hydroxyethyl starch (HES; Hespan, Dupont, Bethlehem, PA, USA) was added to the anticoagulated cord blood. The cord blood volume was reduced, and the cord blood was frozen in 10% dimethylsulfate oxide (DMSO; Cryoserve Research Industry, Salt Lake City, UT, USA), and stored. Units were frozen by controlled rate freezing and stored in liquid nitrogen according to the procedures of Rubinstein et al. 15 
Cell counts
Nucleated cell counts were determined with the automated Coulter STKS (Beckman-Coulter, Hialeah, FL, USA). Differential counts were performed on Wright-Giemsa stained smears (CMS Protocol; Fisher, Pittsburgh, PA, USA).
CD34 assay
Umbilical cord blood (5 ϫ 10 5 cells) was incubated with anti-CD45 fluorescein (FITC) and anti-CD34 phycoerythrin (PE; Becton Dickinson, San Jose, CA, USA) for 10 min at room temperature then lysed with FACS Lysing Solution (Becton Dickinson). Following several washes with FACS flow (Becton Dickinson) to remove unbound antibody, the cells were fixed in 0.5% paraformaldehyde and stored at 4°C until analysis. Fifty thousand live events per tube were acquired in the FACScan (Becton Dickinson). CD34 + cells were selected based upon their forward and 90°scatter properties and dim CD45 expression.
CFU-GM
Cord blood was lysed using ammonium chloride (Stem Cell Technologies, Vancouver, BC, Canada) and resuspended in 2% bovine serum albumin (Calbiochem-Novabiochem Corp, La Jolla, CA, USA). Cells were plated at a concentration of 2 ϫ 10 4 cells/ml in methylcellulose medium containing 50 ng/ml stem cell factor, 10 ng/ml GM-CSF and 10 ng/ml IL-3 (Stem Cell Technologies). Plates were incubated at 37°C for 14 days.
A colony was defined as a cluster of cells containing at least 40 cells. Counts were reported as a mean of three plates.
Viability
Viability was determined using a trypan blue dye exclusion method. The non-viable cells stain deep blue.
Statistics
Descriptive statistics are presented for each maternal and neonatal factor. The Spearman rank correlation and the Kruskal-Wallis test are used for univariate analyses. Multivariate linear regression is used to test for association between mutually adjusted maternal and neonatal characteristics (independent variables) and log-transformed laboratory measurements (dependent variables). The fitted coefficients from the regression analyses are exponentiated to obtain the estimated proportion difference in outcome levels associated with each independent variable. The level of statistical significance is set at 0.05 (two-sided). 16 
Results
Characteristics of the donating mothers and babies, including maternal age, smoking status, number of previous live births, gestation duration, birth weight, baby's sex, and donor's self-reported racial background are outlined in Table 1 . The mean maternal age was 30 years with a range of 18-44 years. Eight percent of the donating mothers reported that they were current smokers -the number of pack-years was not assessed. Five hundred and seventyeight donors were delivering their first babies, 451 second babies, 178 third, and 62 more than third. The analysis only included previous live births and did not take into account other pregnancies that did not result in live births. The mean gestation duration was 39.8 weeks, with a range of 37-42 weeks. The mean birth weight was 3625 g with a range of 2155-5925 g. Forty-eight percent of the babies were female and 52% male.
Racial designations were categorized into seven groups: African/African American, Asian/Asian American, Caucasian, Hispanic, Native American, mixed minority race, and other. Eighty-five percent of the donors were Caucasians, while 15% were minority and/or mixed. Paternal race data were similar (results not shown). There was no clear correlation between the different racial groups and any of the laboratory parameters tested. Therefore, race was excluded in subsequent analyses.
Summary laboratory statistics are included in Table 2 . The mean volume was 106 ml (including 35 ml of anticoagulant), with a range of 75-218 ml. The mean total nucleated cell (TNC) count was 94 ϫ 10 7 (range 25-348), the mean total mononuclear cell count (MNC) was 39 ϫ 10 7 (range 2-149), and mean total CFU-GM 2.3 ϫ 10 6 9 Table 1 Characteristics of donor and baby (range 0.04-39.6). The mean total CD34 + cell count was 3.1 ϫ 10 6 (range 0.07-25.2). The mean viability was 95% (range 70-100%). The volume of cord blood collected was strongly positively correlated with CD34 + cell counts, CFU-GM, cell counts and viability (P Ͻ 0.001). The close range of viability results (50% of results between 97% and 100%) eliminated the use of viability as an outcome indicator for the maternal and neonatal factors.
The results of the univariate analyses are presented in Table 3 , where the distribution of volume, total nucleated count, CD34
+ cells, and CFU-GM are outlined in relation to the same factors. Maternal age had no effect on any of the outcome measures. Women who were smokers produced cord blood units with significantly lower median CD34
+ cell counts than non-smokers (2.0 ϫ 10 6 vs 2.4 ϫ 10 6 , P = 0.04). The effect of smoking on the volume of the cord blood unit, total nucleated cell count, and CFU-GM was less apparent.
Among the neonatal factors examined, birth order had a significant effect, with the first baby having higher volume, cell counts, CD34
+ cell counts, and CFU-GM. As shown in Table 3 , the first baby had a median CD34 + cell count of 2.6 ϫ 10 6 , second baby 2.4 ϫ 10 6 , third baby 1.9 ϫ 10 6 , and subsequent babies 1.3 ϫ 10 6 (P Ͻ 0.001). There was a similar decrease in the volume of cord blood colBone Marrow Transplantation lected, CFU-GM, and cell counts with each subsequent live birth.
Even within the close range of term babies (37-42 weeks), the effect of a longer gestational age was found to be associated with a higher nucleated cell count (P Ͻ 0.001), but it has a slightly negative effect on CFU-GM (P = 0.01). No significant effect of gestational age on the volume of cord blood collected or the CD34 + cell count was observed.
The birth weight of the baby positively correlated with all the laboratory variables. Bigger babies were more likely to produce cord blood units with larger volumes, higher cell counts, CFU-GM, and CD34
+ cell counts (all P Ͻ 0.05, Table 3 ). The birth weight of the babies analyzed in this study ranged from 2155 to 5925 g; therefore, none of these babies met the Ballard standard for small for gestational age. 17, 18 Female babies had significantly lower median CFU-GM results (1.3 ϫ 10 6 for female babies vs 1.5 ϫ 10 6 for male babies, P Ͻ 0.001), but the effect of the gender of the baby was less evident in the volume of cord blood collected, the CD34 + cell counts, or total nucleated cell count. Multivariate analysis was performed to assess the effect of the maternal and neonatal factors while mutually adjusting for each other. The results are outlined in Table  4 . Birth weight, gestational age and birth order show significant effects on the laboratory parameters. For example, each additional prior birth contributed to a 3% decrease in volume, a 12% decrease in total nucleated count, a 17% decrease in CD34
+ cell count and an 18% decrease in CFU-GM. Each additional week of gestation contributes to a 3% increase in total nucleated cell count, but a 9% decrease in CD34
+ cell counts and an 11% decrease in CFU-GM. Each 500 gram increase in birth weight contributed to a 6% increase in volume, an 11% increase in total nucleated count, a 28% increase in CD34
+ cell count and a 22% increase in CFU-GM. The effect of smoking was confounded by factors such as parity and birth weight; smokers tended to have more children and produce smaller babies. Thus, after mutual adjustment of other factors in the multivariate model, the effect of smoking diminished. Donor age had no effect in the multivariate analysis. The gender of the baby also had no effect in the multivariate analysis, except for CFU-GM; male babies' CFU-GM levels were 14% higher than female babies. In all analyses, similar findings were obtained when the analysis was restricted to the 1084 Caucasian donors.
Discussion
Umbilical cord blood is a useful alternative stem cell source for patients without matched family donors. A significant difference between cord blood and traditional bone marrow is the smaller number of cells obtained in the cord blood product. For example, an acceptable standard for allogeneic bone marrow is 2 ϫ 10 8 NC/kg; for cord blood it is a log lower at 2 ϫ 10 7 NC/kg. 19 Initial studies did not show a survival advantage based on cell dose, colony-forming For continuous predictors, the correlation with cord blood CFU-GM content is presented in Spearman rank correlation coefficient (r), where a value of +1.0 indicates perfect positive and −1.0 indicates perfect negative correlation. b For categorical predictors, descriptive statistics are given for each category and compared using the non-parametric Kruskal-Wallis test.
assays, or CD34 + cell counts. 9, 20 However, more recent studies of unrelated umbilical cord blood recipients indicate that the nucleated cell dose/kg infused correlated with engraftment and survival. 10, 11 Expansion of cord blood cells, after culturing with cytokine combinations, is being studied as a method of increasing the progenitor cells, but is still work in progress. 21, 22 Our analysis is descriptive and represents the largest series of its kind, and the first to study birth order and gesBone Marrow Transplantation tational age. The parameters tested, CFU-GM, CD34
+ cells and nucleated cell count, are the parameters most frequently used in clinical practice to predict engraftment. These parameters serve as surrogates for engraftment. As the number of cord blood transplants increases over the next few years, we may be able to extend this analysis to study the effect of the maternal and neonatal variables on engraftment after cord blood transplantation.
In our analysis, volume, as expected, is clearly associated with higher cell counts, CFU-GM and CD34 + cell counts. Many cord blood banks have set a lower limit of acceptable volume, such as 40-60 cc without anticoagulant. 14, [23] [24] [25] Cord blood can be collected either before or after the delivery of the placenta; in our program, the cord blood is collected by trained obstetrical staff before the delivery of the placenta. 26 Early cord blood clamping may increase the volume of collection, but raises ethical concerns, and is not generally practised. 27, 28 One study observed a circadian variation to cord blood parameters; cord blood collected between 4 am and 12 noon had the lowest CFU-GM. 29 Race and maternal age showed no effect on the laboratory parameters that were assessed. The difficulties of minority recruitment have been previously described. 30 The high percentage of Native American donors is unique to our cord blood bank; however, the racial designations are self-reported, and there is concern that some mothers may have interpreted the term 'Native American' as 'born in the United States'. 30 In all the analyses, similar findings were obtained if the non-Caucasian donors were included. The National Heart Lung and Blood Institute (NHLBI) sponsored cord blood study uses a maternal age of 35 as a cutoff. 31 Our study indicates there is no loss of hematopoietic potential in babies delivered to women between the ages of 35 and 40. Our study did not analyze other issues that may be related to older mothers, such as birth defects.
The deleterious effect of smoking on neonatal outcome has been well described in the obstetrical literature. 32, 33 The cord blood of neonates of smoking mothers has been shown to have lower neutrophil and reticulocyte counts, but similar hemoglobin and platelet counts compared with neonates of non-smoking mothers. 34 Smokers tend to have smaller babies, and have a higher incidence of birth anomalies. Eight percent of our cord blood donors smoked during pregnancy, which is consistent with previous reports. 35 The number of pack-years was not assessed on the registration form. Smokers produced cord blood units with lower CD34
+ cell counts than non-smokers; however, smokers also had smaller babies (associated with lower CD34 + cell counts) and more babies (also associated with lower CD34 + cell counts). When adjusting for these other co-variates in the multivariate analysis, no significant effect of smoking was found.
A surprising result was the effect of birth order on CD34 + cell count, CFU-GM and total cell counts. First babies had the most favorable values, with the results falling with each successive previous live birth. This effect was also significant in the multivariate analysis; each previous live birth contributed a 17% decrease in CD34 + cell count and a 12% decrease in total nucleated count. Therefore, there appears to be a loss of hematopoietic potential with each subsequent birth. The study analysis did not take into account other pregnancies, such as spontaneous or induced abortions, which did not result in live births. The association between the number of pregnancies (live birth or not) and cord blood hematopoietic potential may best be addressed in a future prospective study.
The etiology for this finding is unclear. Speculative hypotheses include a weakening of the placental vasculature. First babies are also associated with a longer labor; longer labor has been reported to be associated with higher total nucleated cell counts. 36 There are no convincing data to support stem cell exhaustion or an aging effect in this setting.
All babies were of gestational age between 37 and 42 weeks according to American Red Cross Cord Blood Program policies. Babies of older gestational age were bigger, as expected, and had higher cell counts. However, the CFU-GM and CD34
+ cell counts dropped with gestational age, suggesting a loss of hematopoietic potential with gestational age. This finding was also significant in the multivariate analysis; each week of gestation contributed a 9% decrease in CD34 + cell counts and an 11% decrease in CFU-GM. These results suggest that it may be appropriate or cost effective to limit cord blood collections after a certain gestational age, such as 40 weeks. Data on fetal hematopoiesis show high levels of circulating progenitor cells, higher than in term cord blood; our data are consistent with a decrease in hematopoietic potential with longer gestational age. 37 An inverse relationship between gestational age and CD34 expression has been previously described. 38, 39 As anticipated, bigger babies were associated with cord blood units with higher cell counts, CFU-GM and CD34 + cell numbers. In multivariate analysis, each 500 g increase in birth weight contributed an 11% increase in total nucleated count, a 28% increase in CD34
+ cell counts and a 22% increase in CFU-GM. Birth weight was the most significant of all the neonatal variables.
One previous analysis in the literature, with only 62 cord blood samples, reported that greater cell counts were obtained from bigger babies, Caucasian donors, and women with longer first stages of labor, and with minimal or no alcohol and tobacco use. 40 We did not find any association with race, studying over 1200 cord blood samples, perhaps due to the small proportion (15%) of non-Caucasian donors and possible misclassification, which would bias the results towards the null. A recent study of 114 collections reported that volume of blood collected, length of gestation, and length of labor positively correlated with a higher nucleated cell count; CFU-GM and CD34
+ cell counts were not studied as outcome indicators. 36 Our study suggests that cord blood banks can use maternal and neonatal predictors to process the optimal cord blood units. The current policy of many cord blood banks is to exclude cords based on volume collected or nucleated cell counts. 31 However, this policy incurs the cost of collection and collection personnel, laboratory testing and laboratory personnel. Other banks may use post-processing statistics such as nucleated cell count recovery or CFU-GM or CD34
+ cell count. Since CD34 + cell counts, CFU-GM, processing and freezing the cord unit is costly, of the order of several hundred dollars, a cost effective strategy would be to select the units most likely to be transplanted to process and freeze.
Our data suggest that cord units should be selected without regard to race, maternal age, or sex of the baby. Optimal results would be obtained by selecting first or second babies, babies with a gestational age less than or equal to 40 weeks, and weight Ͼ3600 g.
The cost of cord blood processing is one of the limiting factors to the rapid expansion of cord blood banks; some centers calculate 4 or more years of operation before recovery of costs. 41 The use of the above strategies may allow cord blood banks to efficiently collect more units and achieve the goal of offering transplantation to patients who previously had no donor.
